BACKGROUND: There is limited available evidence regarding the role of monitoring serum gentamicin concentrations in peritoneal dialysis (PD) patients receiving this antimicrobial agent in gram-negative PD-associated peritonitis. METHODS: Using data collected in all patients receiving PD at a single center who experienced a gram-negative peritonitis episode between 1 January 2005 and 31 December 2011, we investigated the relationship between measured serum gentamicin levels on day 2 following initial empiric antibiotic therapy and subsequent clinical outcomes of confirmed gram-negative peritonitis. RESULTS: Serum gentamicin levels were performed on day 2 in 51 (77%) of 66 first gram-negative peritonitis episodes. Average serum gentamicin levels on day 2 were 1.83 ± 0.84 mg/L with levels exceeding 2 mg/L in 22 (43%) cases. The overall cure rate was 64%. No cases of ototoxicity were observed. Day-2 gentamicin levels were not significantly different between patients who did and did not have a complication or cure. Using multivariable logistic regression analysis, failure to cure peritonitis was not associated with either day-2 gentamicin level (adjusted odds ratio (OR) 0.96, 95% confidence interval (CI) 0.25 - 3.73) or continuation of gentamicin therapy beyond day 2 (OR 0.28, 0.02 - 3.56). The only exception was polymicrobial peritonitis, where day-2 gentamicin levels were significantly higher in episodes that were cured (2.06 ± 0.41 vs 1.29 ± 0.71, p = 0.01). In 17 (26%) patients receiving extended gentamicin therapy, day-5 gentamicin levels were not significantly related to peritonitis cure. CONCLUSION: Day-2 gentamicin levels did not predict gentamicin-related harm or efficacy during short-course gentamicin therapy for gram-negative PD-related peritonitis, except in cases of polymicrobial peritonitis, where higher levels were associated with cure.
BACKGROUND: There is limited available evidence regarding the role of monitoring serum gentamicin concentrations in peritoneal dialysis (PD) patients receiving this antimicrobial agent in gram-negative PD-associated peritonitis. METHODS: Using data collected in all patients receiving PD at a single center who experienced a gram-negative peritonitis episode between 1 January 2005 and 31 December 2011, we investigated the relationship between measured serum gentamicin levels on day 2 following initial empiric antibiotic therapy and subsequent clinical outcomes of confirmed gram-negative peritonitis. RESULTS: Serum gentamicin levels were performed on day 2 in 51 (77%) of 66 first gram-negative peritonitis episodes. Average serum gentamicin levels on day 2 were 1.83 ± 0.84 mg/L with levels exceeding 2 mg/L in 22 (43%) cases. The overall cure rate was 64%. No cases of ototoxicity were observed. Day-2 gentamicin levels were not significantly different between patients who did and did not have a complication or cure. Using multivariable logistic regression analysis, failure to cure peritonitis was not associated with either day-2 gentamicin level (adjusted odds ratio (OR) 0.96, 95% confidence interval (CI) 0.25 - 3.73) or continuation of gentamicin therapy beyond day 2 (OR 0.28, 0.02 - 3.56). The only exception was polymicrobial peritonitis, where day-2 gentamicin levels were significantly higher in episodes that were cured (2.06 ± 0.41 vs 1.29 ± 0.71, p = 0.01). In 17 (26%) patients receiving extended gentamicin therapy, day-5 gentamicin levels were not significantly related to peritonitis cure. CONCLUSION: Day-2 gentamicin levels did not predict gentamicin-related harm or efficacy during short-course gentamicin therapy for gram-negative PD-related peritonitis, except in cases of polymicrobial peritonitis, where higher levels were associated with cure.
Authors: Beth Piraino; George R Bailie; Judith Bernardini; Elisabeth Boeschoten; Amit Gupta; Clifford Holmes; Ed J Kuijper; Philip Kam-Tao Li; Wai-Choong Lye; Salim Mujais; David L Paterson; Miguel Perez Fontan; Alfonso Ramos; Franz Schaefer; Linda Uttley Journal: Perit Dial Int Date: 2005 Mar-Apr Impact factor: 1.756
Authors: David W Johnson; Hannah Dent; Carmel M Hawley; Stephen P McDonald; Johan B Rosman; Fiona G Brown; Kym M Bannister; Kathryn J Wiggins Journal: Am J Kidney Dis Date: 2008-09-21 Impact factor: 8.860
Authors: R J van der Hulst; E W Boeschoten; F W Nielsen; D G Struijk; W D Dreschler; R A Tange Journal: ORL J Otorhinolaryngol Relat Spec Date: 1991 Impact factor: 1.538
Authors: P Nikolaidis; S Vas; V Lawson; L Kennedy-Vosu; A Bernard; G Abraham; S Izatt; S Khanna; J M Bargman; D G Oreopoulos Journal: Perit Dial Int Date: 1991 Impact factor: 1.756
Authors: Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; Philip Clayton; David W Johnson Journal: Perit Dial Int Date: 2012-09-01 Impact factor: 1.756
Authors: Dwarakanathan Ranganathan; Saiyuri Naicker; Steven C Wallis; Jeffrey Lipman; Sharad K Ratanjee; Jason A Roberts Journal: Perit Dial Int Date: 2015-10-22 Impact factor: 1.756
Authors: John Henry McDermott; Joshua Wolf; Keito Hoshitsuki; Rachel Huddart; Kelly E Caudle; Michelle Whirl-Carrillo; Peter S Steyger; Richard J H Smith; Neal Cody; Cristina Rodriguez-Antona; Teri E Klein; William G Newman Journal: Clin Pharmacol Ther Date: 2021-06-20 Impact factor: 6.875
Authors: Caspar J Hodiamont; Annemieke K van den Broek; Suzanne L de Vroom; Jan M Prins; Ron A A Mathôt; Reinier M van Hest Journal: Clin Pharmacokinet Date: 2022-06-27 Impact factor: 5.577
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson Journal: Perit Dial Int Date: 2016-06-09 Impact factor: 1.756